Segment Wealth Management LLC Increases Holdings in Johnson & Johnson (NYSE:JNJ)

Segment Wealth Management LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 3,357 shares of the company’s stock after buying an additional 270 shares during the period. Segment Wealth Management LLC’s holdings in Johnson & Johnson were worth $485,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Legal Advantage Investments Inc. boosted its stake in shares of Johnson & Johnson by 62.7% during the 4th quarter. Legal Advantage Investments Inc. now owns 2,596 shares of the company’s stock worth $375,000 after acquiring an additional 1,000 shares in the last quarter. Hamlin Capital Management LLC boosted its stake in shares of Johnson & Johnson by 9.6% during the 4th quarter. Hamlin Capital Management LLC now owns 1,076,740 shares of the company’s stock worth $155,718,000 after acquiring an additional 94,147 shares in the last quarter. Sugar Maple Asset Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $60,000. Mitchell & Pahl Private Wealth LLC boosted its stake in shares of Johnson & Johnson by 4.2% during the 4th quarter. Mitchell & Pahl Private Wealth LLC now owns 18,174 shares of the company’s stock worth $2,628,000 after acquiring an additional 739 shares in the last quarter. Finally, Ballentine Partners LLC raised its position in shares of Johnson & Johnson by 2.6% during the 4th quarter. Ballentine Partners LLC now owns 57,853 shares of the company’s stock worth $8,367,000 after purchasing an additional 1,461 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on JNJ. Leerink Partners cut their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday. Raymond James cut their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Guggenheim boosted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Nine investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.06.

Johnson & Johnson Stock Up 0.9 %

Shares of Johnson & Johnson stock opened at $146.58 on Friday. The company has a fifty day moving average price of $148.10 and a 200 day moving average price of $156.05. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The stock has a market cap of $352.91 billion, a price-to-earnings ratio of 21.21, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.29 EPS. Equities research analysts forecast that Johnson & Johnson will post 9.95 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.